// App-Quantinova.ai

3085 : The BET family bromodomain inhibitor ABBV-075 targets multiple pathogenesis factors in multiple myeloma and exhibits robust in vivo efficacies as a single agent and in combination with bortezomib

Researchers

Presenter

  • Tamar Uziel

Principal Investigators

  • Xiaoyu Lin

  • Emily Faivre

  • Aparna Sarthy

  • Daniel H. Albert

  • Leiming Li

  • Denise Wilcox

  • Xiaoli Huang

  • Terry Magoc

  • Lloyd Lam

  • Steven W. Elmore

  • Keith McDaniel

  • Warren Kati

  • Yu Shen

Medical Centers

  • AbbVie, Inc., North Chicago, IL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Solid malignancies

Biomarkers

  • Interferon regulatory factor 8

  • Interleukin 6

Drug/Treatment

  • Bortezomib

  • abbv-075

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved